When a company reverses its own landmark acquisition at the moment its stock is working, long-term investors should pay attention. CVS Health announced it will split into two separate public companies by the first half of 2028, undoing the vertically integrated model it built when it paid roughly $78 billion for Aetna in 2018. It is one of the largest corporate breakups on record, and it arrives not from weakness but, in management's words, "from a position of strength."
The structure is straightforward. The insurance business and the Caremark pharmacy benefit manager, joined by Oak Street Health, Signify Health and specialty drugs, keep the CVS Health name under CEO David Joyner. The roughly 9,000 retail pharmacies become CVS Pharmacy, led by Prem Shah. Existing shareholders will own both companies. The pieces are not small: about $37.7 billion of 2025 sales in pharmacy, $36.3 billion in insurance, and $51.2 billion in healthcare services. Third-quarter revenue rose to $108.4 billion from $102.9 billion a year earlier, and results beat expectations.
The timing says as much as the decision. Shares have climbed about 70% since Joyner took over in October 2024, lifting market value to around $117 billion, as a turnaround built on $2 billion of cost cuts, store closures and tighter Medicare Advantage cost control gained traction. Management is choosing to simplify while the market is rewarding it. The backdrop also matters: pharmacy benefit managers face bipartisan scrutiny in Washington, Congress passed PBM reforms in February, and states are increasingly restricting PBM ownership of pharmacies. One Leerink analyst called the split a complete shock, and suggested the logic may partly be to sidestep relentless legislative pressure on vertical integration.
For patient investors, breakups of this kind deserve a measured read. Separation can sharpen capital allocation, make each business easier to value on its own merits, and give management teams clearer accountability. A standalone retail pharmacy that has been winning share and stabilizing margins may be judged differently than one buried inside a conglomerate. But the costs are real: duplicated overhead, stranded synergies, and a long runway of nearly two and a half years in which execution risk sits alongside regulatory risk. The Aetna deal was once sold as the future of healthcare; its unwinding is a reminder that scale does not always equal durable advantage.
The so-what for long-term investors: do not treat the headline as a catalyst, treat it as a prompt to reassess what each piece is worth. A 70% rebound has already repriced much of the turnaround, so the question is whether two focused companies can earn better returns on capital than one sprawling one, and how regulatory pressure on PBM economics shapes the insurance-and-Caremark half. Watch segment margins, capital return plans and balance sheet allocation as details emerge. In a story that will take until 2028 to resolve, patience and the discipline to compare price against steady cash generation will matter more than the first-day reaction.